5ehc
From Proteopedia
(Difference between revisions)
m (Protected "5ehc" [edit=sysop:move=sysop]) |
|||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Co-crystal structure of eIF4E with nucleotide mimetic inhibitor.== | |
- | + | <StructureSection load='5ehc' size='340' side='right' caption='[[5ehc]], [[Resolution|resolution]] 2.40Å' scene=''> | |
- | + | == Structural highlights == | |
- | + | <table><tr><td colspan='2'>[[5ehc]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5EHC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5EHC FirstGlance]. <br> | |
- | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=5NX:3-[[(2~{R},3~{S},4~{R},5~{R})-5-[2-AZANYL-7-[(3-CHLOROPHENYL)METHYL]-6-OXIDANYLIDENE-1~{H}-PURIN-7-IUM-9-YL]-3,4-BIS(OXIDANYL)OXOLAN-2-YL]METHYLAMINO]-4-OXIDANYL-CYCLOBUT-3-ENE-1,2-DIONE'>5NX</scene></td></tr> | |
- | [[ | + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2v8w|2v8w]]</td></tr> |
- | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ehc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ehc OCA], [http://pdbe.org/5ehc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ehc RCSB], [http://www.ebi.ac.uk/pdbsum/5ehc PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ehc ProSAT]</span></td></tr> |
- | [[Category: | + | </table> |
- | [[Category: Walkinshaw, M | + | == Disease == |
+ | [[http://www.uniprot.org/uniprot/IF4G1_HUMAN IF4G1_HUMAN]] Defects in EIF4G1 are the cause of Parkinson disease type 18 (PARK18) [MIM:[http://omim.org/entry/614251 614251]]. An autosomal dominant, late-onset form of Parkinson disease. Parkinson disease is a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.<ref>PMID:21907011</ref> | ||
+ | == Function == | ||
+ | [[http://www.uniprot.org/uniprot/IF4E_HUMAN IF4E_HUMAN]] Its translation stimulation activity is repressed by binding to the complex CYFIP1-FMR1 (By similarity). Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures. Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap.<ref>PMID:16271312</ref> [[http://www.uniprot.org/uniprot/IF4G1_HUMAN IF4G1_HUMAN]] Component of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome. | ||
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Fischer, P M]] | ||
+ | [[Category: Nowicki, M W]] | ||
+ | [[Category: Walkinshaw, M D]] | ||
+ | [[Category: Complex]] | ||
+ | [[Category: Eif4e]] | ||
+ | [[Category: Inhibitor]] | ||
+ | [[Category: Translation]] |
Revision as of 21:03, 10 September 2016
Co-crystal structure of eIF4E with nucleotide mimetic inhibitor.
|